
Cutaneous lupus erythematosus is a heterogeneous autoimmune condition that can significantly impact quality of life. Treatment is focused on reducing clinical inflammation and preventing scarring. The choice of treatment should be guided based on the severity of disease. Mild or localized disease can be treated with sun protection and topical agents. Antimalarials are the initial treatment of choice if systemic therapy is required. Patients with severe or unresponsive disease can also be treated with a number of other immunomodulating or immunosuppressive agents. Clinicians should be aware of their potential adverse effects and appropriate dosing.
Inflammation, Severity of Illness Index, Antimalarials, Cicatrix, Lupus Erythematosus, Cutaneous, Quality of Life, Sunlight, Humans, Immunologic Factors, Dermatologic Agents, Immunosuppressive Agents
Inflammation, Severity of Illness Index, Antimalarials, Cicatrix, Lupus Erythematosus, Cutaneous, Quality of Life, Sunlight, Humans, Immunologic Factors, Dermatologic Agents, Immunosuppressive Agents
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 13 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
